Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349307 | 1.00 | CHRM1 (0.43) | CHRM1CHRM3CHRM2CHRM4DRD2 | |
| SCHEMBL5356706 | 1.00 | CHRM1 (0.43) | CHRM1CHRM3CHRM2CHRM4DRD2 | |
| SCHEMBL13315495 | 0.88 | CCNT1 (0.35) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13404426 | 0.88 | CCNT1 (0.35) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13385037 | 0.88 | CCNT1 (0.35) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13349394 | 0.88 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13603525 | 0.88 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13404424 | 0.88 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13385036 | 0.88 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13315492 | 0.88 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205410-B2 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| EP-1140915-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-09-25 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | HRH2, ALK, CBR1 | CHRM1 216/4885CHRM3 267/4885CHRM2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.